News
To Enhance Biologics Dual Acquisition Done By Recipharm
Recipharm, the Swedish CDMO, which happens to be Moderna’s COVID-19 vaccine production partner, has undergone not one but two acquisitions in the week ending February 19th. This expansion is a part of a strategy that Recipharm has been eyeing...
News
Xanadu Licences Intranasal Vaccine Booster To Stop Virus
Xanadu Bio, in association with Yale University, has come up with a nanoparticle delivery platform that will help to position itself to give its expertise in the COVID-19 booster vaccines that may prove to be more efficient in stopping...
News
Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics
Recipharm, a global contract development and manufacturing organisation (CDMO), is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a...
News
Moderna And Rovi Extend Mrna Manufacturing Collaboration
A contract extension has been put in place between Moderna, Inc. and Spain’s Rovi, which shall cover the production of formers vaccine doses, including any future mRNA-based drugs as well as immunizations. Notably, the contract between the two organisations...
News
World’s First Monoclonal Antibody Prequalifies To Treat COVID
In order to increase access to treatments that are recommended to fight COVID-19, the WHO has added a monoclonal antibody treatment called Tocilizumab to its list of prequalified options to treat the virus. Currently, the WHO has given a nod...
News
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
Collegium Pharmaceutical, Inc. and BioDelivery Sciences International, Inc. announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.
BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions....
News
ImmunityBio Completes Acquisition of Athenexs Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
ImmunityBio, Inc., a clinical-stage immunotherapy company announced the successful completion of its acquisition of the leasehold interest in an ISO Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex, Inc. (NASDAQ: ATNX).
The new state-of-the-art...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read